香港科技大學
2009-2010
年報
50
研究與發展
RESEARCH AND DEVELOPMENT
HKUST 2009-2010 Annual Report
51
Commercialization and Business
Development
HKUST strives to make a contribution to economic
development in Hong Kong and the region by nurturing
talent, by technology diffusion and transfer processes,
by intellectual property protection and licensing, and by
the incubation of start-up companies.
Nurturing talent is considered the most effective means
of technology diffusion. Most of the 1,364 master’s and
146 doctoral graduates of 2009 moved into the private
and public sectors, taking with them in-depth knowledge
of their discipline, and an ability to create and innovate.
These graduates, and indeed those at the bachelor’s level,
are a force for change, and play a significant role in our
transition to a knowledge-based society.
•
HKUST has been allocated $575.5 million by the
Innovation and Technology Fund (ITF) over the 10-
year period 1999-2009 (i.e. since the beginning
of the ITF program) - far more than any other
institution in Hong Kong.
•
Over this same period, HKUST received $577.8
million in industrial funding for contract research and
collaborative R&D.
The University’s Technology Transfer Center (TTC) and
HKUST R and D Corporation Ltd (RDC) work to establish
university-industry collaboration, R&D partnerships, the
protection and licensing of intellectual property and
assisting spin-off companies. Examples include:
•
The HKUST LED-FPD Technology R&D Center at
Foshan was formally established in June 2010. The
Center, with funding support from the Foshan
Government, will strengthen the University’s research
infrastructure and activities in the Pearl River Delta
region and provide a platform to secure collaboration
opportunities and funding sources on the Mainland.
•
Prof Karl Tsim, Department of Biology, developed a
hair-based drug testing technology as an alternative
to other drug testing methods such as the urine
drug test commonly used in Hong Kong. The High
Performance Liquid Chromatograph-Chip-Mass
Spectrometry, a new technology, can trace a person’s
drug-taking history over the previous three months
or more –detailing what drugs have been taken,
when, and the actual dosage.
•
HKUST signed an agreement on 8 December
2009 with GlaxoSmithKline R&D China (GSK R&D
China), a subsidiary of GSK which is the world’s
second largest pharmaceutical company, to conduct
collaborative research at the newly established
GSK R&D China - HKUST Neuroscience Laboratory.
This partnership is unique as it brings together
the pharmaceutical expertise in industry and the
biological expertise within academia to address an
important and challenging area of neuroscience. This
partnership is expected to lay the foundations for
initiatives in neuro-drug development and boost drug
development in Hong Kong.
•
Prof Reinhard Renneberg, Department of Chemistry,
has established a start-up company R&C Biogenius
Limited which filed a patent entitled Lipocalin-2
as a Prognostic and Diagnostic Marker for Heart
and Stroke Risks (WO/2009/132510) in 2009.
Another start-up company he has established, DNA
SuperNova Limited, is currently collaborating with
Merck & Co., Inc. to develop a rapid test for detection
of Campylobacter Jejuni which is the main cause
of bacterial food-borne disease in many developed
countries. He has also collaborated with Shenzhen
Kang Sheng Bao Biotechnology Co., Limited to
develop a CardioCare hs-CRP ELISA with CE and
SFDA approvals, an InfectCheck CRP ELISA with
CE mark and an InfectCheck NeoPT rapid test with
CE mark. In addition, he has collaborated with GC
Corporation in Japan to develop a rapid test for
detection of Streptococcus Sobrinus in saliva, which
can be used to predict the risk of dental caries.
•
Perception Digital, founded in 1999 by Prof Jack Lau,
Prof CY Tsui and Prof Roger Cheng, was listed on the
Growth Enterprise Market (GEM) in December 2009
to raise approximately HK$100 million in capital.
高登研究會議
科大成功舉辦2010年分子及細胞神經生物學高登研究會
議，更是第一個在亞洲舉行的高登研究會議。這個國際頂
級的學術會議對促進美國及亞洲神經科學家相互交流起了
積極作用。
首個國家重點實驗室
國家科技部已批准科大成立分子神經科學國家重點實驗
室，有助科大在現有基礎上進一步發展分子神經科學。實
驗室獲授國家資格，肯定了我們在神經學研究上的傑出學
術成就。生物化學系講座教授葉玉如教授獲委任為實驗室
創辦主任。該實驗室將作為世界級研究的基礎，吸引及培
育傑出研究人員，並為學術交流提供穩固的平台。
商業化及商務發展
科大透過培育人才、技術拓展及轉移、保障知識產權及特
許經營，以及培育創業公司，全力協助香港及區內的經濟
發展。
培養人才是科技拓展最有效的途徑。科大於2009年共有
1,364名碩士畢業生及146名博士畢業生，大部分投身公
營部門或私營機構，將他們所修讀學科的豐富知識、專業
技術、創意及創新能力引進各行業。這群畢業生以至學士
畢業生皆為創新的生力軍，在我們轉型向知識型社會的過
程中擔當重要角色。
•
1999-2009年的10年間（自創新及科技基金計劃推行
以來），科大獲創新及科技基金撥款5.755億港元，金
額遠超香港任何院校。
•
同期，科大獲工業界資助5.778億港元，進行合約研究
和合作研發。
科大技術轉移中心及香港科大研究開發有限公司攜手合
作，促成大學與業界的合作計劃、研發夥伴計劃、知識產
權的認證與保障，以及協助成立分拆公司。例子包括：
•
佛山市香港科技大學LED-FPD工程技術研究開發中心
於2010年6月正式成立。在佛山市政府的資助下，中
心將加強科大在珠江三角洲地區的研究基建及活動，
為在內地物色合作機會及發掘資金來源提供平台。
•
生物學系詹華強教授開發了一種頭髮驗毒技術，作為
香港目前常用的尿液驗毒等方法以外的另一選擇。這
種新技術名為液相色譜 — 晶片/多級質譜，它可以追
蹤過去至少三個月的吸毒歷史 — 包括毒品種類、吸毒
時間和每次劑量。
•
科大與全球第二大藥廠葛蘭素史克屬下的葛蘭素史克
中國研發中心於2009年12月8日簽訂合作協議，建立
「葛蘭素史克中國研發中心 — 香港科技大學神經科學
實驗室」。這項合作結合了業內藥物開發與學術界在生
物學研究上的優勢，一同探索神經科學的尖端領域。
是次合作可為神經系統疾病的藥物研發奠下基石，促
進香港醫藥的發展。
